Comprehensive analysis of 2097 patients with dystrophinopathy based on a database from 2011 to 2021.

This is one of the largest studies to have evaluated the natural history of dystrophinopathy in China, which is particularly conducive to the recruitment of eligible patients for clinical trials and the provision of real-world data to support drug development.